市場調查報告書
商品編碼
1064730
心臟麻痺治療的全球市場:2021年~2027年Cardiac Arrest Treatment Market 2021-2027 |
全球心臟麻痺治療的市場規模在預測期間內預計將以大幅年複合成長率擴大。久坐的生活方式習慣,肥胖,糖尿病,抽煙,高膽固醇,高血壓等,對全球心臟驟停治療市場的增長做出了重大貢獻。
本報告提供全球心臟麻痺治療市場相關調查,提供市場概要,以及各治療類型,各地區的趨勢,及加入此市場的主要企業簡介等資訊。
Global Cardiac Arrest Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Drugs, Medical Devices), Forecast (2021 - 2027)
The global cardiac arrest treatment market is anticipated to grow at a considerable CAGR during the forecast period. Higher inclination towards sedentary lifestyle, obesity, diabetes mellitus, smoking, high cholesterol, and high blood pressure among others are the key contributors to the growth of the global cardiac arrest treatment market.
The global cardiac arrest treatment market is segmented based on treatment type. Based on treatment type, the cardiac arrest treatment market is segmented into drug and medical device. The drugs are further sub-segmented into vasopressors, corticosteroid, anti-arrhythmic drugs, and others. The medical device segment is further sub-segmented into defibrillator, cardiac resynchronization therapy, and others.
Geographically, the global cardiac arrest treatment market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. Some of the companies operating in the global cardiac arrest treatment market include ZOLL Medical Corp., General Electric Co., Abbott Laboratories, Stryker Corp., Boston Scientific Corp., and Koninklijke Philips N.V. among others.
Market Segmentation
The Report Covers